company background image
LIFE

Pharmsynthez MISX:LIFE Stock Report

Last Price

₽4.51

Market Cap

₽1.4b

7D

0%

1Y

-23.5%

Updated

05 Oct, 2022

Data

Company Financials
LIFE fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

LIFE Stock Overview

Public Joint-Stock Company ‘Pharmsynthez’, a pharmaceutical company, researches, manufactures, and distributes officinal and generic active pharmaceutical ingredients in Russia and CIS countries.

Public Joint-Stock Company "Pharmsynthez" Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Pharmsynthez
Historical stock prices
Current Share Price₽4.51
52 Week High₽7.00
52 Week Low₽2.65
Beta0.19
1 Month Change0%
3 Month Change10.15%
1 Year Change-23.51%
3 Year Change-0.77%
5 Year Change-62.92%
Change since IPO-81.14%

Recent News & Updates

Recent updates

Shareholder Returns

LIFERU PharmaceuticalsRU Market
7D0%1.5%0%
1Y-23.5%1.9%-38.2%

Return vs Industry: LIFE underperformed the Russian Pharmaceuticals industry which returned 1.1% over the past year.

Return vs Market: LIFE exceeded the Russian Market which returned -38.9% over the past year.

Price Volatility

Is LIFE's price volatile compared to industry and market?
LIFE volatility
LIFE Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement5.4%
Market Average Movement5.6%
10% most volatile stocks in RU Market10.4%
10% least volatile stocks in RU Market2.9%

Stable Share Price: Insufficient data to determine LIFE's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine LIFE's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1996n/aPetr Kurglyakovhttps://www.pharmsynthez.com

Public Joint-Stock Company ‘Pharmsynthez’, a pharmaceutical company, researches, manufactures, and distributes officinal and generic active pharmaceutical ingredients in Russia and CIS countries. The company offers officinal medicines, including Neovir, Segidrin, Fenasid, and Penkrofton that are used in oncology, gynecology, treatment of immune deficiencies, and tuberculosis. Public Joint-Stock Company ‘Pharmsynthez’ has partnership with HiFiBiO Therapeutics Inks for the clinical development and commercialization of its SARS-CoV-2 neutralizing antibody in Russia.

Public Joint-Stock Company "Pharmsynthez" Fundamentals Summary

How do Pharmsynthez's earnings and revenue compare to its market cap?
LIFE fundamental statistics
Market Cap₽1.36b
Earnings (TTM)-₽669.67m
Revenue (TTM)₽451.32m

3.0x

P/S Ratio

-2.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
LIFE income statement (TTM)
Revenue₽451.32m
Cost of Revenue₽244.37m
Gross Profit₽206.95m
Other Expenses₽876.62m
Earnings-₽669.67m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-2.22
Gross Margin45.85%
Net Profit Margin-148.38%
Debt/Equity Ratio86.9%

How did LIFE perform over the long term?

See historical performance and comparison